Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shps Aversi RatsionalifiledCriticalShps Aversi Ratsionali
Priority to GEAU200911262UpriorityCriticalpatent/GEU20101591Y/en
Publication of GEU20101591YpublicationCriticalpatent/GEU20101591Y/en
A tablet contains a kernel containing mononitrate of isosorbide, dioxide of silicon, hypromeloze, polyethylene glycol, povidon, stearate of magnesium and lactose and which is covered by the coating containing a mix of enveloping substances.
Compounds derived from n-phenyl-3- (1h-pyrazol-4-yl) quinoxalin-6-amine, fgfr tyrosine kinase inhibitors; Preparation process; pharmaceutical composition; and its use in the prevention or treatment of cancer.
Pharmaceutical combination comprising a compound derived from biphenylamide and a bcr-abl inhibitor selected from nilotinib; pharmaceutical composition; and use of the combination for the treatment of bcr-abl positive leukemia.
Use of 4-n-butylresorcinol for preventing or reducing the diffusion of one or more components of cosmetic preparations, especially emulsions, into the container material, especially tubes, surrounding the preparation